INTRODUCTION
Heart failure (HF) is a major health and financial burden worldwide. Despite the advances in cardiology, the prevalence of HF is increasing and the outcome remains poor.
During the 90 days following HF hospitalization, hospital readmission and readmission rates are 21-47% and 8-16%, respectively and are supposed to be higher in patients with refractory HF [1, 2] . Although the "transition phase" is the most vulnerable period after hospital discharge, 75% of readmissions in this time may be preventable [3] . The European Society of Cardiology (ESC) guidelines recommended for the first time that patients with HF should be enrolled in a multidisciplinary care management programme to reduce not only the risk of HF hospitalization, but also mortality (Class I, Level of recommendation A) [4] . The first well described day-care HF unit (DCHFU) with multidisciplinary management program was introduced in Sheba Medical Centre, Israel. The safety of the day care service among patients with advanced HF was confirmed with lower than expected hospital readmission and mortality rates [6] . The DCHFU was also introduced as an element of the Coordinated Heart Failure Care Programme (KONS) by the Polish Ministry of Health in 2018 [5] . We hypothesized that the individualized and comprehensive treatment in the DCHFU aimed for maintaining the effect of the hospital treatment may improve patients' prognosis also among those with recurrent rehospitalizations. The purpose of the study was to determine the effects of treatment in DCFHU on the outcomes in refractory HF patients, including hospital readmissions and survival. The second aim was to analyse the insurer's costs of treatment in DCHFU. The treatment costs to the National Health Fund (NHF), the only Polish public insurer, for the 6-month period before inclusion were calculated as the cost of two hospitalizations due to HF according to NHF valuation. The overall costs to NHF during 6-months treatment in DCHFU were calculated as the summary costs of all visits in DHCFU (accounted for outpatient clinic) and all unplanned hospitalizations for acute HF according to NHF valuation.
METHODS

DCHFU
Statistical analysis
Continuous variables with normal distribution were presented as means (SD) and those with other than normal distribution -as medians [IQR] . Categorical variables were presented as percentages.
The investigation conforms with the principles outlined in the Declaration of Helsinki.
The study was approved by the Bioethics Committee of the Medical University of Silesia (KNW/0022/KB1/150/15/16).
RESULTS AND DISCUSSION
Eighty-three patients were enrolled in the study. During the median [IQR] follow-up of 268 [623] days, 2,426 visits were recorded. The baseline characteristics and main results were presented in Table 1 . There were no serious adverse events during the visits in DCHFU.
During the 6-month treatment in DCHFU 3,3% of patients had 2 hospital readmissions due to HF decompensation comparing to at least 2 hospitalizations for acute HF in all participants in the same period before inclusion to DCHFU. Among patients who completed 12-month follow-up, the median [IQR] of estimated 12-month survival rate according to the SHFM was 55.8 [54.0] %, while the observed 12-month survival reached 76.1%. The average treatment costs to NHF during the 6-month period before inclusion to DCHFU were 2.9-fold higher than during the first 6-months of treatment in DCHFU (Table 1) .
Patients included in the study were younger and had higher prevalence of comorbidities than the average Silesian population of HF patients [8] . Comparing to HF patients in COMMIT-HF registry, the age was similar, but the prevalence of comorbidities and concentrations of NT-proBNP were higher, while LVEF was considerably lower [9] .
We showed that simple but individualized care in the day-care unit may reduce the rate of hospital readmissions for acute HF, insurer's costs and improve 12-month survival comparing to the SHFM estimations. Our observations suggest that DCHFU may be designed as a bridge therapy for patients qualified for HTx (36% of patients) or observation list (24%), but also as a destination therapy for patients without possibility of LVAD or HTx (40%).
According to our experience, the day care treatment may be beneficial only to The study has some limitations. There was no control group or possibility of data collection in similar population without treatment in DCHFU. Thus, the results should be interpreted with caution as the only comparison may be done with estimated data or data available in other publications. However, in readmission and cost analyses, the control group was composed of the same patients treated in the same period before inclusion to DCHFU.
The overall costs of DCHFU for the hospital are difficult to assess and were not analyzed in the current study. In our opinion, randomized trials may be difficult to conduct, due to concerns regarding heterogeneity of patients characteristics, limited number of patients and ethical aspects of depriving patients of potentially beneficial treatment in day-care unit.
The day-care heart failure unit seems to be an efficient option for patients with recurrent hospitalizations due to HF which may allow to improve outcomes and reduce insurer's costs. 
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